chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 38.0
Sex: M
Vaccine: COVID19
Symptoms: Conjunctivitis, Eye pain, Ocular hyperaemia, Swelling of eyelid
Clinical narrative: Pink eye (conjunctivitis) both eyes; Soreness, very red around bottom of eye under and around iris, not as much redness on top of eye; Soreness, very red around bottom of eye under and around iris, not as much redness on top of eye; Swelling around bottom eyelid; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206), via an unspecified route of administration in the left arm on 05Apr2021 at 15:00 (at the age of 38-year-old), as a single dose for COVID-19 immunisation. Medical history was reported as none and the patient did not have any history of allergies to food, medications, or other products. Concomitant medications included finasteride (PROPECIA) for an unknown indication from an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07Apr2021, the patient experienced pink eye (conjunctivitis) in both eyes, swelling around bottom eyelid, soreness, very red around bottom of eye under and around iris not as much redness on top of eye. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of events which included treatment with histamine eyedrops. The clinical outcome of the events pink eye (conjunctivitis) in both eyes, swelling around bottom eyelid, soreness, very red around bottom of eye under and around iris, not as much redness on top of eye was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Pain
Clinical narrative: 4/6/21 woke with headache, by 2pm serious headache, chill, body aches and tired.; 4/6/21 woke with headache, by 2pm serious headache, chill, body aches and tired.; 4/6/21 woke with headache, by 2pm serious headache, chill, body aches and tired.; 4/6/21 woke with headache, by 2pm serious headache, chill, body aches and tired.; 4/6/21 woke with headache, by 2pm serious headache, chill, body aches and tired.; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER 8729) via an unspecified route of administration in the left arm on 05Apr2021 at 13:45 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history and other medication received within two weeks of vaccination was not reported. The patient had no known allergies to food, medicine or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021, the patient woke with headache, by 14:00, she experienced serious headache, chill, body aches and tired. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events woke with headache, by 14:00 serious headache, chill, body aches and tired was resolving at the time of report.  No follow-up attempts are needed. No further information is expected.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache
Clinical narrative: Dull HA(headache); Fatigue; This is a spontaneous report from a contactable nurse, the patient. A 69-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via unspecified route of administration on an unspecified anatomical site and the patient also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6205), in the right arm on 23Mar2021 at 08:00 (at the age of 69-year-old) as a single dose for COVID-19 immunisation. Medical history included as HTN (Hypertension), poly Mal, obesity and age. The patient had a history of allergies to NSAIDS. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 09Mar2021 at 10:00, 9-10 days post last vaccination the patient experienced dull HA (headache) and fatigue. The patient reported that little or no reaction day of or one week from last injection.  The patient thought that was interesting and hoped for some reaction post injection to show bodies reaction to immune response and the patient was surprised that they were latent symptoms. No therapeutic measures were taken for the events. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of dull HA(headache) and fatigue was ongoing at the time of report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 33.0
Sex: M
Vaccine: COVID19
Symptoms: Groin pain
Clinical narrative: Groin pain; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the left arm on 02Apr2021 at 12:00 PM (at the age of 33-years-old) as a single dose for COVID-19 immunisation. The patients' medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 06Apr2021, the patient experienced groin pain 3 days after the vaccine dose. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event groin pain was not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Chills, Fatigue, Headache, Malaise
Clinical narrative: Upset stomach; Injection site pain; Soreness in right arm; Tiredness; Headache; Chills; Feeling unwell; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the arm right on 06Apr2021 at 15:45 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included Factor V Leiden, Raynaud, sleep apnea and COVID-19. Concomitant medications included ascorbic acid (VITAMIN C), colecalciferol (VITAMIN D3), calcium (MANUFACTURER UNKNOWN), bifidobacterium infantis, lactobacillus acidophilus (PROBIOTIC) and Multi vitamin; all for an unknown indication and from an unspecified date and unknown if ongoing. The patient previously received nitrofurantoin (MANUFACTURER UNKNOWN) on an unknown date for an unspecified indication and experienced drug allergy. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 07Apr2021 at 10:00, the patient experienced injection site pain, soreness in right arm, tiredness, headache, chills, feeling unwell and upset stomach. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcomes of the events Injection site pain, soreness in right arm, tiredness, headache, chills, feeling unwell and upset stomach were recovering at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Vaccination site pain
Clinical narrative: Upset stomach; Injection site pain; Soreness in right arm; Tiredness; Headache; Chills; Feeling unwell; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the arm right on 06Apr2021 at 15:45 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included Factor V Leiden, Raynaud, sleep apnea and COVID-19. Concomitant medications included ascorbic acid (VITAMIN C), colecalciferol (VITAMIN D3), calcium (MANUFACTURER UNKNOWN), bifidobacterium infantis, lactobacillus acidophilus (PROBIOTIC) and Multi vitamin; all for an unknown indication and from an unspecified date and unknown if ongoing. The patient previously received nitrofurantoin (MANUFACTURER UNKNOWN) on an unknown date for an unspecified indication and experienced drug allergy. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 07Apr2021 at 10:00, the patient experienced injection site pain, soreness in right arm, tiredness, headache, chills, feeling unwell and upset stomach. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcomes of the events Injection site pain, soreness in right arm, tiredness, headache, chills, feeling unwell and upset stomach were recovering at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure decreased, Dizziness
Clinical narrative: I experienced dizziness/lightheadedness and extremely low Blood Pressure Readings; I experienced dizziness/lightheadedness and extremely low Blood Pressure Readings; This is a spontaneous report from a contactable healthcare professional, the patient. A 62-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 30Mar2021 at 13:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history included hypertension, diabetes, cholesterol high (reported as high cholesterol), gastrooesophageal reflux disease (gerd), heart enlarged, arthritis and back disorder (reported as Lumbar problems in back). The patient previously took Celebrec, Tramadol, Sulphur and experienced drug allergy to Celebrec, Tramadol and products with Sulphur. Concomitant medications taken within two weeks prior to the vaccination included hydrochlorothiazide 12.5 milligram, losartan potassium 16 milligram (LOSARTAN HCTZ), omeprazole 40 mg (MANUFACTURER UNKNOWN) (reported as omeprazole DR) and acetylsalicylic acid (ASPIRE) (reported as Aspir); all from unknown date for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 31Mar2021 at 13:30, the patient experienced dizziness/lightheadedness and extremely low blood pressure readings. The events resulted in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken as a result of the events. The clinical outcome of the event dizziness/lightheadedness and extremely low blood pressure readings was resolved on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Hyperhidrosis, Pain, Pyrexia
Clinical narrative: soreness; chills; fever; sweat; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: er8732) via an unspecified route of administration in the right arm on 05Apr2021 at 10:30(at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included diabetes. Concomitant medications were not reported. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the right arm on 15Mar2021 at 16:00 for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 at 09:00, the patient experienced chills, fever, sweat and soreness. The patient did not receive any treatment for the adverse events. The clinical outcome of the events chills, fever, sweat and soreness were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Headache, Heart rate increased, Hot flush
Clinical narrative: Five minutes after injection, experienced a hot flash and increased hart rate, accompanied by dizziness; Five minutes after injection, experienced a hot flash and increased hart rate, accompanied by dizziness; Five minutes after injection, experienced a hot flash and increased hart rate, accompanied by dizziness; Headache persisted for 2 hours; This is a spontaneous report from a non-contactable consumer, the patient. A 32-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 07Apr2021 at 15:00 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. Medical history included anemia, vitamin D deficiency, cilantro (food allergy), sulfa (sulfonamide allergy) and peanut allergy. Concomitant medications included vitamin D (MANUFACTURER UNKNOWN) and antimony potassium tartrate, pulsatilla pratensis, bryonia alba, drosera rotundifolia, psychotria ipecacuanha, dactylopius coccus, rumex crispus, lobaria pulmonaria, euspongia officinalis (CHESTAL BERRY); both for unknown indications and on unknown dates. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07Apr2021 at 15:05, five minutes after vaccination, the patient experienced a hot flash and increased heart rate, accompanied by dizziness. The patient was treated with water and sitting. On 07Apr2021, after returning to normal, the patient experienced headache which persisted for 2 hours. On 07Apr2021, the patient underwent lab tests and procedures which included heart rate and the result was high. Events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the events hot flash, increased heart rate, dizziness and headache was recovered on 07Apr2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia
Clinical narrative: Faint metallic bitter sensation on the back of palette/tongue/sinus area; This is a spontaneous report from a non-contactable consumer, the patient. A 54-year-old non-pregnant female patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ep6955) via an unspecified route of administration on an unknown date in Apr2021 (at age of 54-year-old) as a single dose for COVID-19 immunisation. Medical history included hyperthyroidism, hyperpigmentation skin, penicillin allergy and yeast infections. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On an unknown date in Apr2021, immediately after being injected, the patient felt a faint metallic bitter sensation on the back of the palette/tongue/sinus area. Although it was not an adverse reaction, it had been 25 hours after it began at the time of reporting and nothing had alleviated the sensation. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event of metallic taste was not recovered at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Rash erythematous, Rash papular, Rash pruritic
Clinical narrative: Irritating raised red rash under the arm; Scattered, itchy, irritating raised red rash under the arm; irritating raised red rash under the arm of the arm; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the right arm on 05Apr2021 at 15:45 (at the age of 68-years-old) as a single dose for COVID-19 immunisation. Medical history included prostate cancer.  Patient had no known allergies. Concomitant medications included atorvastatin (MANUFACTURER UNKNOWN), montelukast sodium (SINGULAIR), famotidine (PEPCID), loratadine (CLARITYN), and tadalafil (TADAL) all from an unknown date for an unspecified indication. The patient previously took first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the right arm on 12Mar2021 at 10:30 (at the age of 68-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 at 20:00, the patient experienced scattered, itchy, irritating raised red rash under the arm of the arm the shot was given in, in the armpit covering about 40% to 50% of the skin's surface area. The patient received treatment for the events which included hydrocortisone topical cream and BENADRYL. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events red rash, itchy rash, raised rash was not recovered.  No follow-up attempts are needed. No further information is expected.
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Vertigo
Clinical narrative: Vertigo; This is a spontaneous report from a contactable consumer, the patient. A 65-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 19Mar2021 at 10:00 (at the age of 65-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. The patient was allergic to sulfa drugs. Concomitant medications included losartan potassium (LOSARTIN). The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 26Feb2021 at 11:00 (at the age of 65-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 23Mar2021 at 18:00, 4 days after the vaccination, the patient experienced vertigo. The event was ongoing even after 2 weeks of onset. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event vertigo was not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Contusion, Polymerase chain reaction, Urticaria
Clinical narrative: hives all over body; black and blue bruises; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208), via an unspecified route of administration in the right arm on 15Mar2021 at 12:00(at the age of 48-year-old), as a single dose for COVID-19 immunisation. Medical history included asthma and high blood pressure. Concomitant medications were not reported. The patient did not have any known allergies. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 19Mar2021 at 10:00, the patient broke out in hives all over the body and the patient went to the urgent care and was prescribed hydroxyzine Hcl 25 mg and prednisone 20 mg and had black and blue bruises on the right arm as therapeutic measures for the adverse events. On 19Mar2021, the patient underwent nasal swab and the result was negative. The clinical outcome of the events hives all over body and black and blue bruises was recovered on an unknown date. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737), via an unspecified route of administration in the right arm on 05Apr2021, as a single dose for COVID-19 immunisation.    No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Diarrhoea, Headache, Pain, Pyrexia
Clinical narrative: Horrible and sudden diarrhea.; Chills; Aches; Fever; Headache; Urinary incontentance; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER8732) via an unspecified route of administration in the right arm on 06Apr2021 at 12:15 (at the age of 58-years-old), as a single dose for COVID-19 immunisation. Medical history included thalassemia minor, hypothyroidism and known allergy to sulfa. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN) ,vilazodone hydrochloride (VIIBRYD) and vitamins nos (DAILY VITAMINS); all for unspecified indication from unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6205) via an unspecified route of administration in the right arm on 16Mar2021 at 12:15 (at the age of 58-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07Apr2021 at 13:30, the patient experienced chills, aches, fever, headache, urinary incontinence. On 08Apr2021, the patient experienced horrible and sudden diarrhea. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. The clinical outcome of chills, aches, fever, headache, urinary incontinence and horrible and sudden diarrhea were recovering at the time of report.  No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Urinary incontinence
Clinical narrative: Horrible and sudden diarrhea.; Chills; Aches; Fever; Headache; Urinary incontentance; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER8732) via an unspecified route of administration in the right arm on 06Apr2021 at 12:15 (at the age of 58-years-old), as a single dose for COVID-19 immunisation. Medical history included thalassemia minor, hypothyroidism and known allergy to sulfa. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN) ,vilazodone hydrochloride (VIIBRYD) and vitamins nos (DAILY VITAMINS); all for unspecified indication from unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6205) via an unspecified route of administration in the right arm on 16Mar2021 at 12:15 (at the age of 58-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07Apr2021 at 13:30, the patient experienced chills, aches, fever, headache, urinary incontinence. On 08Apr2021, the patient experienced horrible and sudden diarrhea. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. The clinical outcome of chills, aches, fever, headache, urinary incontinence and horrible and sudden diarrhea were recovering at the time of report.  No follow-up attempts are needed. No further information is expected.
Age: 73.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Gait disturbance, Pain in extremity
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 73-year-old male patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: en6203) via an unspecified route of administration in the left arm on 24Feb2021 at 15:00 (at the age of 73-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history and was in good health. The patient was not aware of allergies to medications, food, or other products. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Feb2021, the patient experienced a very strong pain that was very slow to go away in the left upper arm where the shot was given. It was still there with certain movements. On an unknown date in Feb2021, the patient had shoulder pain. On an unknown date in 2021, weeks later, the patient experienced that the pain moved to left hip and it was hard to walk. The hip pain had subsided, but upper arm and shoulder pain had not gone weeks later. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events left hip pain and were resolved on an unknown date in 2021, while that of upper arm pain, shoulder pain and  hard to walk were resolved with sequelae at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: M
Vaccine: COVID19
Symptoms: Epistaxis
Clinical narrative: Bloody nose about 2 hours after injection; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW953) via an unspecified route of administration in the left arm on 08Apr2021 at 12:45 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history was reported as none. Patient did not receive any other medications within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 08Apr2021 at 14:30, the patient experienced bloody nose about 2 hours after injection. The patient did not receive any treatment for the event. The events did not result in doctor/other health care professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the event bloody nose about 2 hours after injection was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Chest pain, Rash
Clinical narrative: Chest pain; Rash on feet; This is a spontaneous report from a non-contactable consumer, the patient. A 21-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the right arm on 06Apr2021 at 12:15 (at the age of 21-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not have any allergies to medications, food, or other products. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7543) via an unspecified route of administration in the right arm on 16Mar2021 at 12:15 (at the age of 21-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 07Apr2021 at 02:30, the patient experienced chest pain and rash on feet. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. The clinical outcome of the events chest pain and rash on feet was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling of body temperature change, Lymph node pain, Pain in extremity, Vaccination site bruising
Clinical narrative: Lymph nodes in left armpit hurt; Bruise where vaccine was injected; Hot and cold; Arm was a little sore; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the left arm on 06Apr2021 at 10:15 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no allergies to food, medications, or other products. The patient did not receive any medication within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 08Apr2021 at 01:00 on day 3 of vaccination, the patient experienced that lymph nodes in her left arm pit hurt, plus she got a bruise where the vaccine was injected. On 07Apr2021, (last night as of report), the patient felt hot and cold and her arm was a little sore. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events lymph node in left armpit hurt, bruise, felt hot and cold and arm sore were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Vaccination site pain
Clinical narrative: Persistent headache; Soreness at injection site several days post-vaccine; This is a spontaneous report from a non-contactable consumer, the patient. A 28-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732), via an unspecified route of administration on an unknown date at 10:00 as a single dose for COVID-19 immunisation. Medical history was not reported and the patient had a history of allergy to ceclor and sulfa. Concomitant medications included ethinylestradiol; ferrous fumarate; norethisterone acetate (LOESTRIN-FE) from an unknown date for an unknown indication. The patient previously took cefaclor (CECLOR) on an unknown date and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On an unknown date, the patient experienced persistent headache and soreness at injection site several days post-vaccine. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events persistent headache and soreness at injection site several days post-vaccine was not recovered at the time of this report.    No follow-up attempts are possible. No further information is expected.
Age: 27.0
Sex: M
Vaccine: COVID19
Symptoms: Chest discomfort, Fatigue, Pain in extremity, Pyrexia
Clinical narrative: Slight fever; fatigue; soreness in arm; intermittent chest tightness; This is a spontaneous report from a non-contactable consumer, the patient. A 27-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an unspecified route of administration in the arm left on 06Apr2021 at 17:15 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included the patient was diagnosed with COVID-19 on an unknown date, prior to the vaccine. The patient had known allergy to amoxicillin. Concomitant medications were not reported. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07Apr2021 the patient experienced slight fever, fatigue, soreness in arm and intermittent chest tightness. The patient did not receive any treatment for the events. The clinical outcome of the events slight fever, fatigue, soreness in arm and intermittent chest tightness was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Fatigue, Pain in extremity, SARS-CoV-2 test
Clinical narrative: About 5 days after the vaccine I felt dizzy and I still feel dizzy at day 15 after my vaccine on March 25; I felt tired next day; My left arm was sore; This is a spontaneous report from a contactable consumer, the patient. A 60-years-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 25Mar2021 at 13:15 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included migraines. The patient had no known allergies to medications, food or other products. Concomitant medications included erenumab (AIMOVIG) for an unspecified indication, from an unknown date and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 26Mar2021, the patient felt tired the next day and left arm was sore. On 30Mar2021, at 20:00, i.e. 5 days after the vaccination the patient felt dizzy and at day 15 after vaccine the patient still felt dizzy. The patient was concerned about dizziness. No therapeutic measures were taken as a result of reported events. The events resulted in doctor or other healthcare professional office/clinic visit. The patient underwent lab tests and procedures, which included nasal swab test (rapid test) on 06Apr2021 and tested negative. The clinical outcome of the events patient felt tired, left arm was sore and patient felt dizzy and at day 15 after vaccine the patient still felt dizzy was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Back pain, Hypoaesthesia, Pain in extremity
Clinical narrative: Left shoulder pain; back pain; pain and numbness in left hand/fingers; numbness in left hand/fingers; pain in elbow; pain and numbness in left hand/fingers; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 19Mar2021 at 09:00(at the age of 43-year-old) as a single dose for COVID-19 immunisation. Medical history included type 2 diabetes mellitus, allergic to IVP(Intravenous pyelogram) dye, detergents allergy(detergent sensitivity), allergy to legumes and peanut allergy. The patient received medications(unspecified) within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Mar2021 at 08:00, the patient experienced left shoulder, back pain, pain in elbow, pain and numbness in left hand/fingers. The adverse events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The patient received naproxen and tizanidine as the treatment for the reported events. The clinical outcome of the events left shoulder, back pain, pain in elbow, pain and numbness in left hand/fingers were not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Vertigo
Clinical narrative: Bouts of vertigo; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the right arm on 26Mar2021 at 12:30 (at the age of 57-years-old), as a single dose for COVID-19 immunisation. Medical history was reported as none. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN) for unspecified indication from unknown date. The patient's allergies to food, medications, or other products were reported as none. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 07Apr2021, the patient experienced bouts of vertigo. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the event bouts of vertigo was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Myalgia, Nausea
Clinical narrative: Muscle pain; Joint pain; Chills; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 06Apr2021 at 15:00 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient was not allergic to medications, food, or other products. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 06Apr2021 at 22:30, the patient experienced muscle pain, joint pain, chills and nausea. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events muscle pain and joint pain which included treatment with pain relief (unspecified). The clinical outcome of the events muscle pain, joint pain, chills and nausea were resolved on an unknown date in Apr2021 at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Pain, Pyrexia, Vaccination site pain
Clinical narrative: Headache; body aches; fever; chills; sore at injection site; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the right arm on 31Mar2021 at 17:00 (at the age of 45-year-old) as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient did not receive any medication within two weeks of vaccination. The patient had no known allergies to medications, food, or other products. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 01Apr2021 at 05:00, the patient experienced headache, body aches, fever, chills and sore at injection site. No therapeutic measures were taken as a result of adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events headache, body aches, fever, chills and sore at injection site was recovered at the time of this report.   No follow-up attempts are needed. No further information is expected
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Lymph node pain, Lymphadenopathy, Vaccination site pruritus, Vaccination site rash
Clinical narrative: Severe swelling of lymph nodes in left armpit area with significant associated pain; Severe swelling of lymph nodes in left armpit area with significant associated pain; itchy rash around the injection site; itchy rash around the injection site; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the left arm on 06Apr2021 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. Concomitant medication was not reported. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6200), via an unspecified route of administration in the left arm on 16Mar2021 (at the age of 35-year-old), as a single dose for COVID-19 immunisation. The patient was not allergic to any medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07Apr2021 the patient experienced severe swelling of lymph nodes in the left armpit area with significant associated pain. The patient reported that swelling started less than 24 hours after the 2nd vaccine, and it was been over 48 hours since the injection and the swelling and pain level had continued to increase. Additionally, on the same day, the patient had experienced an itchy rash around the injection site that was also increasing in size quickly. The patient reported that she did not experience any of these side effects after her first injection. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events severe swelling of lymph nodes in the left armpit area with significant associated pain and itchy rash around the vaccination site were not recovered at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Rash pruritic
Clinical narrative: Rash presented 4 days post vaccination. Appeared first on face(cheek and temple) also on inner arms, abdomen and hip. Rash appears like bite marks, but no one else in household experienced similar rash  and no known exposure to insects in time frame.; Rash is itchy but responds to topical steroid creams; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 30Mar2021 at 09:45 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included HPV vaccine vlp rl1 4v (yeast) (GARDASIL) on 02Mar2021. The patient previously took Naproxen and experienced drug allergy on an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient received the vaccine, GARDASIL within four weeks prior to the vaccination. On 03Apr2021 at 07:00 the patient experienced rash which presented 4 days post-vaccination. The rash appeared first on face (cheek and temple) also on inner arms, abdomen and hip. The rash appears like bite marks, but no one else in the patient's household experienced similar rash and there was no known exposure to insects in the time frame. The patient reported that the rash was itchy but responded to topical steroid creams. Therapeutic measures were taken as a result of the event which included treatment with topical steroid cream and antihistamines. The events resulted in a visit to the doctors or other healthcare professional office/clinic visit. The clinical outcome of the events rash and itchy rash was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.